Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features Journal Article


Authors: Reiner, A. S.; Alici, Y.; Correa, D. D.; Bossert, D.; Sigler, A. M.; Fournier, D.; Brewer, K.; Goyal, G.; Atkinson, T. M.; Marathe, P.; Mao, J. J.; Panageas, K. S.; Diamond, E. L.
Article Title: Anxiety and depression in patients with histiocytic neoplasms and their associated clinical features
Abstract: Anxiety and depression are common in many cancers but, to our knowledge, have not been systematically studied in patients with histiocytic neoplasms (HNs). We sought to estimate rates of anxiety and depression and identify clinical features and patient-reported outcomes (PROs) associated with anxiety and depression in patients with HNs. A registrybased cohort of patients with HNs completing PROs including the hospital anxiety and depression scale (HADS) from 2018 to 2023 was identified. Moderate or severe anxiety or depression were respectively defined as a score of >= 11 on the HADS anxiety or depression subscales. Associations of variables, including other validated PROs, with moderate or severe anxiety or depression were modeled with logistic regression to estimate odds ratios and 95% confidence intervals. In 215 patients, similar to 1 in 3 met the criteria for anxiety or depression, and 1 in 7 met the criteria for moderate or severe anxiety or depression. These estimates remained stable over a 12-month trajectory. Rates of depression, but not anxiety, significantly differed across HN types, with patients with Erdheim-Chester disease experiencing the highest rate. In addition, neurologic involvement, unemployment, and longer undiagnosed illness interval were significantly associated with increased risk of depression. Financial burden, financial worry, and severe disease-related symptoms were correlated with increased risk of both anxiety and depression. Conversely, increased general and cognitive health-related quality of life (HRQoL) were correlated with decreased risk of both anxiety and depression. In patients with HN, anxiety and depression are prevalent, stable over time, and correlated with financial burden, symptom severity, and HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT03329274.
Keywords: functional assessment; diagnosis; therapy; quality-of-life; cancer-patients; langerhans cell histiocytosis; cognitive function; erdheim-chester disease; financial burden; consensus recommendations
Journal Title: Blood Advances
Volume: 9
Issue: 6
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2025-03-25
Start Page: 1376
End Page: 1386
Language: English
ACCESSION: WOS:001448988400001
DOI: 10.1182/bloodadvances.2024014850
PROVIDER: wos
PMCID: PMC11957516
PUBMED: 39626273
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Eli L. Diamond -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anne S Reiner
    251 Reiner
  2. Yesne Alici
    94 Alici
  3. Denise D Correa
    83 Correa
  4. Thomas Michael Atkinson
    155 Atkinson
  5. Katherine S Panageas
    519 Panageas
  6. Dana F Bossert
    13 Bossert
  7. Eli Louis Diamond
    205 Diamond
  8. Jun J Mao
    247 Mao
  9. Allison Marie Sigler
    36 Sigler